

Table 1. Progression-free survival. Results of pairwise comparisons with sunitinib (all risk groups combined)

Intervention	RCT number (name)	Risk of Bias*	Progression-free survival HR [95% CI]	Clinically relevant in favour of
Lenvantinib + Pembrolizumab	NCT02811861a (CLEAR)	High (D3, 4)	0.39 [0.32, 0.48]	Lenvantinib + Pembrolizumab
Nivolumab + Ipilimumab	NCT02231749 (Checkmate 214)	High (D4)	0.89 [0.76, 1.05]	-
Pembrolizumab + Axitinib	NCT02853331 (KEYNOTE-426)	High (D5)	0.68 [0.58, 0.80]	Pembrolizumab + Axitinib
Nivolumab + Cabozantinib	NCT03141177 (CHECKMATE 9ER)	High (D3, 5)	0.51 [0.41, 0.64]	Nivolumab + Cabozantinib
Cabozantinib	NCT01835158 (CABOSUN)	Some concerns (D5)	0.48 [0.31, 0.74]	Cabozantinib
Pazopanib	NCT00720941 (COMPARZ)	Low	1.05 [0.90, 1.22]	-
Nintedanib	NCT01024920	High (D4, 5)	1.12 [0.70, 1.80]	-
Temsirolimus	NCT00979966	High (D1 t/m 5)	1.76 [0.70, 4.44]	sunitinib
Atezolizumab + Bevacizumab	NCT01984242b (IMmotion150)	High (D4, 5)	1.00 [0.69, 1.45]	-
	NCT02420821	High (D4)	0.83 [0.71, 0.98]	-
Atezolizumab	NCT01984242a	High (D4, 5)	1.19 [0.82, 1.72]	-
Everolimus	NCT01108445 (ASPEN)	High (D4, 5)	1.41 [0.87, 2.28]	sunitinib
	NCT00903175 (RECORD-3)	High (D4, 5)	1.40 [1.14, 1.71]	sunitinib
Lenvantinib + Everolimus	NCT02811861b (CLEAR)	High (D3, 4)	0.65 [0.53, 0.80]	Lenvantinib + Everolimus
Sorafenib	NCT00732914 (SWITCH)	High (D4, 5)	1.19 [0.93, 1.53]	-

* D1 Bias arising from the randomization process

D2 Bias due to deviations from intended intervention

D3 Bias due to missing outcome data

D4 Bias in measurement of the outcome

D5 Bias in selection of the reported result